Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy

NCT01243268 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01243268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01243268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
December 21, 2010
Completion date
August 18, 2016
Enrollment
674 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension